The aim of this study is to evaluate tumor necrosis factor (TNF) inhibitor persistence and the
impact of comorbidity on treatment persistence in patients with rheumatoid arthritis (RA). In a …

Objectives This study examined and compared the persistence of adalimumab, etanercept,
infliximab, or abatacept as first-and subsequent-line treatment for rheumatoid arthritis in the …

Aims: We aimed to assess treatment persistence of tumor necrosis factor (TNF) inhibitors
and non-TNF inhibitors in two groups of rheumatoid arthritis (RA) patients: biologic disease …

Objective. To evaluate persistence with anti-tumor necrosis factor (TNF) therapy and
predictors of discontinuation in patients with rheumatoid arthritis (RA). Methods. This …

Background The concerns about the development of adverse events (AEs) in elderly RA
patients as a result of age-related changes in drug metabolism and the presence of …

Objective To compare persistence with tumor necrosis factor alpha (TNF) antagonists
among rheumatoid arthritis patients in British Columbia. Treatment persistence has been …

Objective Tumor necrosis factor-α (TNF) inhibitors have transformed management of
rheumatoid arthritis (RA); however, many patients discontinue TNF inhibitors. Our goal was …

Objective. To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors
adalimumab, etanercept, and infliximab among patients with longstanding rheumatoid …

Objective Tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of severe
rheumatoid arthritis (RA), yet drug discontinuation is common. The aim of this study was to …

Objectives To evaluate TNF-α inhibitor (TNFi) persistence when used as first-or second-line
biologic therapy for the management of PsA, and to determine baseline clinical and …